How Much Heparin Intraperitoneally Is Necessary in CAPD?

E. Gries a
D. Paar a
N. Graben b
K.D. Bock b

aDivision of Clinical Chemistry and Laboratory Medicine, and bDivision of Renal and Hypertensive Diseases, Department of Medicine, University of Essen, FRG

Dr. E. Gries, Medizinische Klinik, Universitätsklinikum Essen, Hufelandstrasse 55, D-4300 Essen 1 (FRG)

Dear Sir,

The intraperitoneal heparin concentration in CAPD is based on clinical observations [1, 2] and differs from center to center [3]. The aim of an intraperitoneal heparinization should be a sufficient inhibition of intraperitoneal fibrin formation without a systemic anticoagulatory effect. The determination of fibrinopeptide A (FPA), a specific marker for thrombin action on fibrinogen, enables the control of fibrin monomer production by thrombin [4, 5]. In 6 patients with diabetic end-stage renal failure we investigated the FPA concentration in dialysate after 500 and 7,500 U heparin/l dialysate for a dwell time of 4h (table I).

Intraperitoneal heparin reduces the fibrin production measurable as FPA concentration. There was no difference between 7,500 and 500 U/l heparin intraperitoneally.

During the experiments with 500 U/l heparin one additional patient got peritonitis (by Achromobacter xylo-soxidans) with an increase of total protein from 58.9 to 209.8 mg/dl and of antithrombin III (AT III) from 0.32 to 1.04 mg/dl in 4-hour dialysate. The FPA concentration remained at 6.3 ng/ml as in his heparinized dialysate without peritonitis. There was no increased fibrinogen cleavage.

A second patient with end-stage renal failure, CAPD treatment and an extended myocardial infarction in the past got peritonitis by Pseudomonas aeruginosa. The initial leukocytosis in dialysate was 23,000/µl. The peritonitis was treated successfully with intraperitoneal ticarcillin and with 500 U heparin per liter dialysate for some weeks. Ten weeks after the peritonitis the patient died of sudden ventricular fibrillation. At autopsy the peritoneum had a glossy surface without any fibrin deposits or visible alterations.

Table I. Concentrations in dialysate after a 4-hour dwell time (x ± SEM)

<table>
<thead>
<tr>
<th>Heparin, U/l</th>
<th>7,500</th>
<th>500</th>
<th>0</th>
</tr>
</thead>
<tbody>
<tr>
<td>AT III, mg/dl</td>
<td>0.33 ± 0.06</td>
<td>0.44 ± 0.13</td>
<td>0.45 ± 0.07</td>
</tr>
<tr>
<td>FPA, ng/ml</td>
<td>20.6 ± 5.6*</td>
<td>22.8 ± 6.0*</td>
<td>152.2 ± 11.8</td>
</tr>
</tbody>
</table>

* Significant versus dialysate without heparin (p < 0.05).

We suggest that the application of 500 U heparin per liter of dialysate is enough to inhibit the intraperitoneal fibrin formation. In addition, we could show in two patients that fibrin formation was suppressed even during peritonitis.

References